Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on May 07, 2017 7:12pm

217 Views

Post# 26214550

RE:RE:RE:RE:RE:RE:RE:TODAY's VOLUME

Thank you, ToInv. I think we pretty much agree.

I think that comment by DM regarding pharma contacts may have been from the December AGM if memory serves me right. I think he stated things narrowly in his comment... but as you stated this would need to be checked.

Let's see what happens over the next several weeks. I think one way or another we are going to hear something new... although it might just be a new financing arrangement. Impossible to say at this point, darn it.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale